| Literature DB >> 35889349 |
Lory Sthephany Rochín-Hernández1, Lory Jhenifer Rochín-Hernández2, Luis Bernardo Flores-Cotera1.
Abstract
Endophytes, microorganisms that live in the internal tissues and organs of the plants, are known to produce numerous bioactive compounds, including, at times, some phytochemicals of their host plant. For such reason, endophytes have been quoted as a potential source for discovering bioactive compounds, particularly, of medical interest. Currently, many non-communicable diseases are threatening global human health, noticeably: diabetes, neurodegenerative diseases, cancer, and other ailment related to chronic inflammation and ageing. Intriguingly, the pathogenesis and development of these diseases have been linked to an excessive formation and accumulation of advanced glycation end products (AGEs). AGEs are a heterogeneous group of compounds that can alter the conformation, function, and lifetime of proteins. Therefore, compounds that prevent the formation and consequent accumulation of AGEs (AntiAGEs compounds) could be useful to delay the progress of some chronic diseases, and/or harmful effects of undue AGEs accumulation. Despite the remarkable ability of endophytes to produce bioactive compounds, most of the natural antiAGEs compounds reported in the literature are derived from plants. Accordingly, this work covers 26 plant antiAGEs compounds and some derivatives that have been reported as endophytic metabolites, and discusses the importance, possible advantages, and challenges of using endophytes as a potential source of antiAGEs compounds.Entities:
Keywords: AGEs detoxification; RAGEs antagonists; carboxymethyl-lysine; diabetes; endophytic metabolites; methylglyoxal; protein glycation
Mesh:
Substances:
Year: 2022 PMID: 35889349 PMCID: PMC9322667 DOI: 10.3390/molecules27144469
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Endogenous AGEs formation in human body. AGEs are typically formed in three phases. The early phase involves the Maillard reaction between sugar and proteins and concludes with the formation of Amadori products. Subsequently, the propagation phase generates α-dicarbonyl compounds such as methylglyoxal, glyoxal, and 3-deoxyglucosone. A great variety of AGEs emerge during the final phase. In addition, other pathways that could exacerbate the quantity of AGEs precursors comprise sugar autoxidation, aminoacids metabolism, lipids peroxidation, polyol pathway, fructolysis, and glycolysis. Created with BioRender.com. Adapted from Zeng et al. [6].
Figure 2Diseases linked to high levels of AGEs accumulation. The excessive formation or accumulation of AGEs and their interaction with RAGEs contribute to the pathogenesis and development of diabetic complications, different kinds of cancer, and neurodegenerative and inflammatory diseases. Created with BioRender.com.
Figure 3The mechanisms of action of antiAGEs compounds. The antiAGEs compounds could restrict in different ways, shown with a red cross, the undue accumulation, and consequent harmful effects of AGEs. These compounds may block sugar attachment to proteins, scavenge free radicals, chelate ions, trap reactive dicarbonyl species, break AGEs cross-links, or block the AGEs–RAGEs interaction. Hyperglycemic control and inhibition of aldose reductase or sorbitol dehydrogenase may decrease the reducing sugars available and, therefore, the formation of AGEs. Created with Biorender.com.
Anti-AGE compounds reported as metabolites synthesized by endophytes.
| AntiAGEs | Concentration/Study Model | Action Mechanism | Endophytic Source/Host Plant | Analytical Method of Identification |
|---|---|---|---|---|
| Protocatechuic acid | * 2–4% in powder diet of T2D rats [ | Reduces formation of CML, pentosidine and the expression of aldose reductase, sorbitol dehydrogenase, and RAGEs. Improves glyoxalase I expression and insulin sensibility. It has antioxidant, hypoglycemic and anti-inflammatory activity [ | -NID endophytes/ | -HPLC-PDA a |
| Gallic acid | * 50–200 µg/mL in BSA-glucose system [ | Diminishes fluorescent AGEs formation and RAGEs expression. Chelates ion metals entrap carbonyl species and have antioxidant, anti-inflammatory and hypoglycemic activities [ | - | -HPLC-DAD b |
| Coumaric acid | * 0.2 mM in rat hepatocytes [ | Decreases collagen cross-links and cytotoxicity induced by GO and MGO in hepatocytes, has antioxidant and anti-inflammatory activity [ | - | -HPLC-DAD b |
| Caffeic acid | * 0.5–2 mM in BSA-MGO and histones-MGO system [ | Reduces the levels of CML, fluorescent AGEs and inflammatory hormones. Inhibits aldose reductase, sorbitol dehydrogenase activity and RAGEs expression, has antioxidant, anti-inflammatory activities [ | -Four | -HPLC-DAD b |
| Ferulic acid | * 50–200 µg/mL in BSA-glucose system [ | Inhibits production of CML, fluorescent AGEs, dicarbonyl compounds, CEL, and melanoidins. Decreases cytotoxicity induced by GO and MGO in hepatocytes, reduces protein cross-linking and has antioxidant, anti-inflammatory and antihyperglycemic activities [ | -NID endophytes/ | -HPLC-PDA a |
| Rosmarinic acid | * 6.25–400 µg/mL in BSA-glucose, BSA-GO and BSA-MGO system [ | Inhibits formation of fluorescent AGEs, CML, and CEL. Reduces MGO levels, protein aggregation, and fibril formation induced by AGEs in human serum albumin [ | -Two | -HPLC-DAD b |
| Chlorogenic acid | * 0.5–2 mM in BSA-MGO and histones-MGO system [ | Inhibits production of fluorescent AGEs and alpha glycosidases. Reduces cross-linking of AGEs-BSA to collagen, entraps MGO, has antihyperglycemic and antioxidant activities [ | - | -HPLC, UPLC-PDA-QTOF-MS b |
| Apigenin (A) and derivatives (V = vitexin and I = isovitexin) | * AGEs IC50 = 85.2–185.2 µM in BSA-glucose-fructose system; aldose reductase IC50 A = 2.47–6.67 µM in RLAR system [ | Inhibits aldose reductase and acetylcholinesterase activities, as well as the formation of fluorescent AGEs. Entraps MGO and reduces inflammatory cytokines and adhesion molecules, has antioxidant and anti-inflammatory activities [ | - | -HPLC-ESI-MS b |
| Kaempferol and derivatives | * 2–4 mg/kg b.w/day in rats; 1–5 µM in YPEN cells [ | Inhibits aldose reductase and entraps dicarbonyl compounds. Reduces AGEs levels and hyperglycemia, suppressing AGEs–RAGEs axis activation. It has antioxidant and anti-inflammatory activities [ | - | -TLC b, HPLC-UV b, 1H, 13C NMR a |
| Luteolin and derivatives | * AGEs IC50 = 16.5–88.9 µM in BSA-glucose-fructose system; aldose reductase IC50 A = 0.087–0.94 µM in RLAR system [ | Inhibits aldose reductase, and production of pentosidine and other fluorescent AGEs. Reduces protein cross-linking [ | - | -HPLC-DAD-ESI-MS a, 1H, 13C, HSQC, and HMBC NMR |
| Quercetin and derivatives | * 50–200 µg/mL in BSA-glucose system [ | Inhibits aldose reductase, and the formation of alpha dicarbonyl compounds, CML, and fluorescent AGEs. Entraps MGO and GO, and reduces cross-linking of proteins and glucose autooxidation, chelates metal ions, has antioxidant activity [ | - | -HPLC-DAD-ESI-MS a, 1H, 13C, HSQC, and HMBC NMR |
| Catechin | * 50–200 µg/mL in BSA-glucose system [ | Inhibits the formation of fluorescent AGEs. Chelates metal ions, entraps dicarbonyl compounds, and has antioxidant activity [ | - | -HPLC-DAD b |
| Daidzein | * 1 mM in MGO system [ | Entraps MGO [ | - | -ESI-MS a, 1H, 13C NMR a |
| Genistein | * 100 µM in BSA-glucose, BSA-ribose and BSA-MGO system [ | Chelates metal ions, entraps MGO, has antioxidant activity [ | - | -ESI-MS a, 1H, 13C NMR a |
| Icariin | * 20 mg/kg/day in diabetic rats [ | Reduces blood glucose levels in diabetic rats, has antioxidant, anti-inflammatory and antihyperglycemic activities [ | - | -HPLC-DAD b |
| Rutin and derivatives | * 50–100 mg/kg body weight in diabetic rats (review) [ | Inhibits alpha-glucosidases, alpha-amylases, aldose reductase, intestinal carbohydrate absorption, and AGEs formation. Increases glucose uptake and insulin secretion. Reduces activity of enzymes involved in gluconeogenesis and has antioxidant and anti-inflammatory activities [ | - | -HPLC-DAD b |
| Resveratrol | * 5 mg/kg b.w. in diabetic rats [ | Inhibits aldose reductase, alpha-glucosidase, alpha-amylase, and sorbitol dehydrogenase. Chelates metal ions and entraps dicarbonyls. Improves insulin sensitivity, glyoxalase-I activity, and adiponectin levels. Reduces AGEs levels in diabetic rats, has antioxidant and anti-inflammatory activities [ | - | -HPLC-dual λ * |
| Tyrosol | * 5–20 mg/kg b.w. in normal and diabetic rats [ | Inhibits alpha-glucosidase, relieves hyperglycemia, and has antioxidant activity [ | - | -HPLC a, 1H, 13C NMR a |
| Ellagic acid | * Aldose reductase IC50 = 0.27 µM in HRAR and IC50 = 0.047 µM in RLAR system [ | Inhibits aldose reductase and sorbitol dehydrogenase activities. Reduces production of CEL, CML, and fluorescent AGEs. Entraps dicarbonyl compounds. Enhances insulin signaling, adiponectin receptors, glucose transporters, and inflammatory mediators. Decreases blood glucose levels and has anti-inflammatory activity [ | - | -HPLC-DAD b |
| Ginsenosides (Rb, Rd, Rg) | * AGEs IC50 = 15–220 µM in BSA-fructose-glucose system [ | Inhibits production of fructosamine, fluorescent AGEs, and CML. Reduces levels of amyloid cross-B structure, has hypoglycemic activity [ | - | -HPLC-UV, HPLC-ESI-MS b |
| Tanshinones | * 5 and 20 mg/kg/day in transgenic mice [ | Reduces plasma glucose, AGEs levels, and RAGE expression. Suppress the activation of NF-κB signaling pathway mediated by RAGE, has anti-inflammatory activity [ | - | -HPLC-HRMS/MS b |
| Stigmasterol | * 0.1 mg/mL in BSA-glucose system [ | Inhibits formation of fluorescent AGEs and protein glycoxidation. Entraps carbonyl intermediates, blocks lysyl residues of BSA, and consequently reduces its binding with glucose. It has antioxidant activity [ | - | -ESI-MS, 1H-NMRa |
| Emodin | * AGEs IC50 = 118 µM in BSA-fructose-glucose system, aldose reductase IC50 = 15.9 µM in RLAR system [ | Inhibits aldose reductase activity and formation of fluorescent AGEs and CML. Entraps MGO, has antioxidant activity [ | - | -Metabolomic analysis by LC-HRMS/MS ab |
| Umbelliferone | * AGEs IC50 = 2.95 ± 0.02 µM in BSA-fructose-glucose system [ | Inhibits production of alpha-glycosidase, alpha-amylase, aldose reductase, fluorescent AGEs, and alpha-dicarbonyl compounds. Improves insulin secretion and glucose uptake, has antioxidant and hypoglycemic activities [ | - | -HPLC-DAD b |
| Matrine | * 50–100 mg/kg in transgenic mice, 10–50 µM | Inhibits RAGEs activation, has anti-inflammatory activity [ | - | -HPLC-PAD b |
| Hypericin | * 1–10 µM in BSA-MGO system, 0.01–0.5 µM in HUVEC-MGO system [ | Inhibits production of α-glucosidase and fluorescent AGEs. Protects against MGO-induced apoptosis and oxidative damage [ | - | -HPLC-HRMS *, detection of |
MGO: methylglyoxal; GO: glyoxal; NID: not identified; CML: carboxymethyl lysine; CEL: carboxyethyl lysine; ROS: reactive oxygen species; BSA: bovine serum albumin; HSA: human serum albumin; RLAR: rat lens aldose reductase; HRAR: human recombinant aldose reductase; b.w.: body weight; HUVEC: human umbilical vein endothelial cells; HPLC-PDA: high-performance liquid chromatography coupled to a photodiode array detector; DAD: diode array detector; ESI: electrospray ionization; MS/MS: mass spectrometry in tandem; HRMS: high-resolution mass spectrometry; dual λ: dual wavelength absorbance detector; UPLC: ultra-performance liquid chromatography; 1H and 13C NMR: proton and carbon nuclear magnetic resonance; HSQC: heteronuclear single quantum coherence NMR; HMBC: heteronuclear multiple bond correlation NMR; OHR-LC-MS: orbitrap high-resolution liquid chromatography coupled to mass spectrometry; APCI: atmospheric pressure chemical ionization; TLC: thin layer chromatography; UV: ultraviolet; IR: infrared spectroscopy; QToF-MS: quadrupole time of flight mass spectrometry; FABMS: fast atom bombardment mass spectrometry; IT: ion trap. a Comparing with database or literature. b Comparing with standard data processed under the same conditions. * Quantitative method.
Figure 4AntiAGEs phenolic acids reported as metabolites in endophytes.
Figure 5AntiAGEs flavonoids reported in endophytes. * Endophytes are also able to produce derivatives of these compounds.
Figure 6Other antiAGEs phenolic compounds reported in endophytes.
Figure 7AntiAGEs terpenoids reported in endophytes.
Figure 8Other antiAGEs compounds reported in endophytes.